PriceTargets.com logo

Cytokinetics - CYTK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $83.67
  • Forecasted Upside: 66.60%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$50.22 As of 11/15/2024 01:00 AM ET
▼ -4.48 (-8.19%)

This chart shows the closing price for CYTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytokinetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTK

Analyst Price Target is $83.67
▲ +66.60% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $83.67, with a high forecast of $120.00 and a low forecast of $60.00. The average price target represents a 66.60% upside from the last price of $50.22.

This chart shows the closing price for CYTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 16 contributing investment analysts is to moderate buy stock in Cytokinetics. This rating has held steady since November 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024Royal Bank of CanadaInitiated CoverageOutperform$80.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
10/18/2024Cantor FitzgeraldReiterated RatingOverweight
10/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
10/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
10/9/2024HC WainwrightBoost TargetBuy ➝ Buy$90.00 ➝ $120.00
9/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
9/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
9/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$65.00 ➝ $71.00
9/4/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$78.00 ➝ $78.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
9/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
8/13/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral$85.00 ➝ $60.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
6/24/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$77.00 ➝ $65.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
6/4/2024B. RileyLower TargetBuy ➝ Buy$122.00 ➝ $92.00
5/29/2024Truist FinancialLower TargetBuy ➝ Buy$86.00 ➝ $70.00
5/28/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$106.00 ➝ $78.00
5/23/2024Bank of AmericaLower TargetNeutral ➝ Neutral$70.00 ➝ $60.00
5/23/2024HC WainwrightLower TargetBuy ➝ Buy$94.00 ➝ $90.00
5/23/2024BarclaysLower TargetOverweight ➝ Overweight$100.00 ➝ $95.00
5/23/2024Raymond JamesLower TargetOutperform ➝ Outperform$92.00 ➝ $70.00
5/23/2024Needham & Company LLCLower TargetBuy ➝ Buy$108.00 ➝ $72.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$94.00
5/9/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$110.00 ➝ $106.00
5/9/2024OppenheimerLower TargetOutperform ➝ Outperform$107.00 ➝ $106.00
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$108.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$94.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$108.00
4/8/2024Truist FinancialReiterated RatingBuy ➝ Buy$86.00
3/6/2024MizuhoLower TargetBuy ➝ Buy$103.00 ➝ $99.00
3/4/2024OppenheimerReiterated RatingOutperform ➝ Outperform$107.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$94.00
2/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$108.00
1/24/2024UBS GroupDowngradeBuy ➝ Neutral$61.00 ➝ $92.00
1/22/2024MizuhoBoost TargetBuy ➝ Buy$80.00 ➝ $103.00
1/5/2024Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$60.00 ➝ $90.00
12/28/2023Truist FinancialBoost TargetBuy ➝ Buy$60.00 ➝ $86.00
12/28/2023Raymond JamesBoost TargetOutperform ➝ Outperform$63.00 ➝ $92.00
12/27/2023Needham & Company LLCBoost TargetBuy ➝ Buy$60.00 ➝ $108.00
12/27/2023HC WainwrightBoost TargetBuy ➝ Buy$58.00 ➝ $94.00
11/9/2023The Goldman Sachs GroupInitiated CoverageBuy$50.00
11/7/2023B. RileyInitiated CoverageBuy$66.00
11/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$58.00
10/20/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00
10/20/2023HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $58.00
10/9/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$71.00
10/9/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$59.00 ➝ $65.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$59.00
8/15/2023Leerink PartnrsReiterated RatingOutperform
8/15/2023Leerink PartnersInitiated CoverageOutperform$58.00
8/15/2023SVB SecuritiesInitiated CoverageOutperform$58.00
8/4/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$60.00
8/4/2023Needham & Company LLCReiterated RatingBuy$60.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$49.00
6/22/2023JPMorgan Chase & Co.Boost Target$52.00 ➝ $54.00
5/5/2023UBS GroupBoost Target$61.00 ➝ $62.00
4/3/2023UBS GroupLower TargetBuy$67.00 ➝ $61.00
4/3/2023Cantor FitzgeraldLower TargetOverweight$61.00 ➝ $59.00
4/2/2023Bank of AmericaLower Target$50.00 ➝ $42.00
3/31/2023HC WainwrightLower TargetBuy$56.00 ➝ $49.00
3/7/2023Cantor FitzgeraldReiterated RatingOverweight$61.00
3/6/2023MizuhoInitiated CoverageBuy$80.00
3/2/2023The Goldman Sachs GroupLower TargetBuy$56.00 ➝ $48.00
3/2/2023JMP SecuritiesReiterated RatingBuy$71.00
3/1/2023Needham & Company LLCReiterated RatingBuy$58.00
3/1/2023OppenheimerLower TargetOutperform$55.00 ➝ $54.00
2/17/2023Bank of AmericaInitiated CoverageNeutral$49.00
1/17/2023The Goldman Sachs GroupBoost TargetBuy$47.00 ➝ $56.00
12/23/2022Needham & Company LLCLower TargetBuy$60.00 ➝ $58.00
12/20/2022Truist FinancialInitiated CoverageBuy$60.00
12/16/2022MizuhoInitiated CoverageBuy$80.00
12/15/2022UBS GroupLower TargetNeutral$80.00 ➝ $66.00
12/15/2022The Goldman Sachs GroupLower TargetBuy$55.00 ➝ $47.00
12/15/2022HC WainwrightBoost TargetBuy$29.00 ➝ $56.00
12/14/2022OppenheimerLower Target$55.00
12/14/2022HC WainwrightLower Target$75.00 ➝ $29.00
12/14/2022JMP SecuritiesLower TargetMarket Outperform$82.00 ➝ $71.00
12/9/2022JPMorgan Chase & Co.Lower Target$64.00 ➝ $55.00
12/8/2022HC WainwrightReiterated RatingBuy$75.00
10/11/2022UBS GroupInitiated CoverageBuy$80.00
10/3/2022JMP SecuritiesBoost TargetMarket Outperform$53.00 ➝ $82.00
9/2/2022MizuhoInitiated CoverageBuy$80.00
8/15/2022Cantor FitzgeraldBoost Target$56.00 ➝ $69.00
8/12/2022Morgan StanleyBoost Target$11.00 ➝ $15.00
8/5/2022Raymond JamesBoost Target$54.00 ➝ $63.00
7/15/2022Morgan StanleyBoost TargetOverweight$46.00 ➝ $60.00
6/9/2022Piper SandlerBoost TargetOverweight$50.00 ➝ $72.00
5/24/2022HC WainwrightReiterated RatingBuy$75.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$71.00 ➝ $57.00
5/16/2022MizuhoBoost TargetBuy ➝ Buy$54.00 ➝ $80.00
5/5/2022Needham & Company LLCBoost Target$52.00 ➝ $60.00
4/29/2022HC WainwrightBoost Target$69.00 ➝ $75.00
2/17/2022Cantor FitzgeraldLower Target$57.00 ➝ $53.00
1/28/2022The Goldman Sachs GroupInitiated CoverageBuy$74.00
12/21/2021OppenheimerInitiated CoverageOutperform$55.00
12/21/2021HC WainwrightBoost TargetBuy$62.00 ➝ $69.00
12/10/2021JPMorgan Chase & Co.Initiated CoverageOverweight$58.00
12/1/2021MizuhoBoost TargetBuy$45.00 ➝ $54.00
11/4/2021HC WainwrightBoost TargetPositive ➝ Buy$58.00 ➝ $62.00
11/4/2021JMP SecuritiesReiterated RatingBuy
10/12/2021Cantor FitzgeraldBoost TargetOverweight$48.00 ➝ $57.00
10/8/2021HC WainwrightReiterated RatingBuy$58.00
10/8/2021Morgan StanleyBoost TargetOverweight$38.00 ➝ $45.00
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$75.00
9/7/2021BarclaysBoost TargetOverweight$40.00 ➝ $45.00
8/9/2021Piper SandlerLower TargetOverweight$42.00 ➝ $40.00
8/6/2021HC WainwrightBoost TargetBuy$53.00 ➝ $58.00
7/20/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$35.00 ➝ $48.00
7/20/2021BarclaysBoost TargetOverweight$28.00 ➝ $40.00
7/19/2021JMP SecuritiesBoost TargetOutperform ➝ Outperform$26.00 ➝ $44.00
7/19/2021Raymond JamesBoost TargetOutperform$37.00 ➝ $54.00
7/19/2021Piper SandlerBoost TargetPositive ➝ Overweight$25.00 ➝ $42.00
7/19/2021HC WainwrightBoost TargetBuy$41.00 ➝ $53.00
7/19/2021Needham & Company LLCBoost TargetBuy$33.00 ➝ $48.00
7/1/2021MizuhoInitiated CoverageBuy$36.00
5/11/2021MizuhoBoost TargetBuy$26.00 ➝ $36.00
4/19/2021Morgan StanleyBoost TargetOverweight$24.00 ➝ $35.00
3/11/2021Wolfe ResearchInitiated CoverageOutperform$50.00
2/18/2021BarclaysInitiated CoverageOverweight$28.00
1/20/2021HC WainwrightBoost TargetBuy$22.00 ➝ $41.00
12/16/2020Morgan StanleyBoost TargetOverweight$22.00 ➝ $24.00
12/14/2020MizuhoLower TargetBuy$31.00 ➝ $26.00
11/24/2020Raymond JamesReiterated RatingBuy
11/23/2020HC WainwrightLower TargetBuy$43.00 ➝ $22.00
11/16/2020Needham & Company LLCReiterated RatingBuy$33.00
11/16/2020Morgan StanleyLower TargetOverweight$24.00 ➝ $22.00
10/28/2020The Goldman Sachs GroupInitiated CoverageNeutral$16.00
10/12/2020Morgan StanleyLower TargetOverweight$35.00 ➝ $24.00
10/8/2020HC WainwrightLower TargetPositive ➝ Buy$59.00 ➝ $43.00
10/6/2020Cantor FitzgeraldBoost TargetOverweight$41.00 ➝ $48.00
7/23/2020Piper SandlerBoost TargetOverweight$33.00 ➝ $36.00
7/23/2020HC WainwrightBoost TargetBuy$38.00 ➝ $59.00
7/15/2020Cantor FitzgeraldBoost TargetOverweight$29.00 ➝ $41.00
7/15/2020JMP SecuritiesBoost TargetOutperform$23.00 ➝ $29.00
7/14/2020Needham & Company LLCBoost TargetBuy$34.00 ➝ $45.00
7/14/2020Piper SandlerBoost Target$28.00 ➝ $33.00
7/14/2020HC WainwrightBoost TargetBuy$35.00 ➝ $38.00
7/10/2020Raymond JamesInitiated CoverageStrong-Buy$39.00
7/7/2020Morgan StanleyBoost TargetOverweight$29.00 ➝ $35.00
5/23/2020MizuhoInitiated CoverageBuy$31.00
5/12/2020Morgan StanleyBoost TargetOverweight$25.00 ➝ $29.00
5/11/2020HC WainwrightBoost TargetPositive ➝ Buy$30.00 ➝ $35.00
5/7/2020Needham & Company LLCReiterated RatingBuy$24.00
5/4/2020MizuhoInitiated CoverageBuy$31.00
4/27/2020Morgan StanleyReiterated RatingBuy$25.00
4/24/2020HC WainwrightReiterated RatingBuy
4/19/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
4/17/2020Cantor FitzgeraldBoost TargetOverweight$12.00 ➝ $23.00
4/14/2020HC WainwrightReiterated RatingBuy$30.00
4/14/2020Needham & Company LLCReiterated RatingBuy$24.00
4/9/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$14.00 ➝ $25.00
3/31/2020HC WainwrightReiterated RatingBuy$30.00
3/4/2020Needham & Company LLCReiterated RatingBuy$24.00
2/26/2020HC WainwrightReiterated RatingBuy$30.00
2/7/2020HC WainwrightReiterated RatingBuy
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2024
  • 20 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
5/21/2024
  • 34 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 15 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 18 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 15 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/18/2024
  • 23 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 16 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 16 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $50.22
Low: $49.86
High: $55.14

50 Day Range

MA: $54.08
Low: $50.22
High: $58.62

52 Week Range

Now: $50.22
Low: $30.68
High: $110.25

Volume

2,342,465 shs

Average Volume

1,131,845 shs

Market Capitalization

$5.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?

The following equities research analysts have issued research reports on Cytokinetics in the last twelve months: B. Riley, Bank of America Co., Barclays PLC, Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, StockNews.com, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for CYTK.

What is the current price target for Cytokinetics?

0 Wall Street analysts have set twelve-month price targets for Cytokinetics in the last year. Their average twelve-month price target is $83.67, suggesting a possible upside of 66.6%. HC Wainwright has the highest price target set, predicting CYTK will reach $120.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $60.00 for Cytokinetics in the next year.
View the latest price targets for CYTK.

What is the current consensus analyst rating for Cytokinetics?

Cytokinetics currently has 4 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CYTK.

What other companies compete with Cytokinetics?

Other companies that are similar to Cytokinetics include Constellation Pharmaceuticals, Zogenix, Intercept Pharmaceuticals, ORIC Pharmaceuticals and Phathom Pharmaceuticals. Learn More about companies similar to Cytokinetics.

How do I contact Cytokinetics' investor relations team?

Cytokinetics' physical mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 624-3000 and its investor relations email address is [email protected]. The official website for Cytokinetics is www.cytokinetics.com. Learn More about contacing Cytokinetics investor relations.